Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials.
about
Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancerSignificant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials.Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis.Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach.
P2860
Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Surrogate endpoints for overal ...... randomised controlled trials.
@en
type
label
Surrogate endpoints for overal ...... randomised controlled trials.
@en
prefLabel
Surrogate endpoints for overal ...... randomised controlled trials.
@en
P2093
P1476
Surrogate endpoints for overal ...... randomised controlled trials.
@en
P2093
Ai-Hua Lin
Wen-Fei Li
Wen-Na Zhang
Yan-Ping Mao
Yu-Pei Chen
P304
P356
10.1016/J.RADONC.2015.07.030
P577
2015-08-01T00:00:00Z